A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nesvategrast (Primary)
Indications Wet age-related macular degeneration
Focus Therapeutic Use
Sponsors OcuTerra Therapeutics; SciFluor Life Sciences

Most Recent Events

18 Dec 2017 Topline results presented in a SciFluor Life Sciences media release.
19 Jul 2017 Status changed from active, no longer recruiting to completed.
07 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Jul 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight